Metsera
Coverage of Metsera in the Nexus archive.
- STAT+: Investor Clive Meanwell on designing biotechs for population health, and AI’s role as a catalyst
Clive Meanwell, chairman of Population Health Partners, leveraged a competitive bidding war between Pfizer and Novo Nordisk for obesity startup Metsera, which reached a $10 billion offer. He now focuses on AI-driven solutions to address large-scale health challenges through innovative technologies and business models.
- STAT+: AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs
Edison Scientific, a spin-off from AI scientist company FutureHouse, was created in late 2025 with $70 million in venture funding after pharmaceutical companies showed interest in their AI agents for drug discovery. FutureHouse, founded in 2023 by Sam Rodriques and Andrew White, initially aimed to scale scientific discovery through AI agents but pivoted to a commercial product due to demand from the pharmaceutical industry.
- STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
Pfizer's obesity drug berobenatide, acquired from Metsera, showed continued weight loss when transitioning from weekly to monthly dosing in a mid-stage study. Patients lost up to 12.1% of their weight by 28 weeks, but the rate lagged behind Eli Lilly's Zepbound trial results.